Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.

BMC Cancer · 2022 · PMC8994226 · PMID 35397511

Europe PMC DOI

hedged sentence

0.1050

closest p · 2.1× alpha

0.1050

boldest claim

The sentences

showed a trendp = 0.105not close (p > 0.1)

However, the results for OS were not significantly different between the two arms, and showed a trend towards longer survival in the sorafenib arm (28.8 vs 29.3 months, respectively; HR: 1.25 [0.95 – 1.62]; p = 0.105).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.